Efficacy of Heart Failure Reversal Therapy (HFRT) in Post-menopausal Female Patients with Preserved Ejection Fraction (>40%)

Purpose: Mortality in women around the world is attributed majorly to CVDs. Around 4.5 Lac women die annually due to plethora of CVDs like Heart Failure (HF) and Ischemic Heart Disease or their complications. Especially, postmenopausal women are majorly affected by CVDs. This study was conducted to evaluate the effect of Heart Failure Reversal Therapy (HFRT) on VO2max, Blood Pressure (BP), Body Mass Index (BMI), abdominal Girth and Heart Rate.

Methods: This observational study was conducted from January 2015 to December 2017, wherein the data of post-menopausal CHF patients (New York Heart Association, NYHA Class I–II) with preserved ejection fraction, who attended out-patient departments (OPDs) at Madhavbaug Hospital in Khopoli, Maharashtra, India were identified. Data of patients who were administered HFRT (60-75 minutes) with minimum 7 sittings over 7 days were considered. Variables were compared between day 1, 7, 30, 60, and day 90 of HFRT.

Results: 71 postmenopausal women were finally enrolled in the study. HFRT showed significant improvement in VO2max from 16.53±4.86 to 24.8±6.25, p<0.001. SBP reduced significantly from 124.03±17.02 to 120.76±12.62 (p-0.56) at the end of 90th day. Heart rate reduced from 85.79±15.12 to 79.58±10.19 (p< 0.001).

Conclusion: HFRT can serve as potent and viable therapeutic option for management of HF in Post-menopausal women with Preserved Ejection Fraction.